AOD-9604

Overview

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176–191) designed to isolate the fat-metabolism (lipolytic) portion of the molecule without the broader GH effects — notably, it is generally reported NOT to raise IGF-1. It is marketed for fat loss. The human evidence is modest: in a 23-week randomized clinical trial, participants on AOD-9604 1 mg/day lost on average about 2.8 kg vs about 0.8 kg on placebo. Importantly, AOD-9604 failed to show sufficient efficacy in later obesity development, and there is no robust, high-quality human evidence that adding it to a GLP-1/GIP therapy produces meaningful additional fat loss. Claims should be treated cautiously.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Fat loss / weight management (marketed claim; modest and mixed human evidence)
• Metabolic / 'lipolytic' support — marketed claim
• Sometimes marketed for joint/cartilage support — limited evidence

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Body weight — daily smart-scale trend with 7-day rolling average
• Body composition — InBody body-fat % and lean mass every 2–4 weeks
• Labs — fasting glucose and lipid panel; note IGF-1 is generally NOT expected to change (useful as a contrast vs. GH secretagogues)
• Nutrition — MyFitnessPal caloric/macros adherence
• Subjective — energy, appetite

Sources & References

1. [1]AOD-9604 randomized clinical trial — fat loss data overview
2. [2]AOD-9604 fat-loss peptide overview and regulatory status — Meto
3. [3]FDA peptide reclassification 2026 — what to know — Loti Labs